Author's Accepted Manuscript

A CRISPR/Cas9 based engineering strategy for overexpression of multiple genes in Chinese hamster ovary cells

Peter Eisenhut, Gerald Klanert, Marcus Weinguny, Laurenz Baier, Vaibhav Jadhav, Daniel Ivansson, Nicole Borth



 PII:
 S1096-7176(18)30075-2

 DOI:
 https://doi.org/10.1016/j.ymben.2018.05.017

 Reference:
 YMBEN1415

To appear in: Metabolic Engineering

Received date: 20 February 2018 Revised date: 25 May 2018 Accepted date: 26 May 2018

Cite this article as: Peter Eisenhut, Gerald Klanert, Marcus Weinguny, Laurenz Baier, Vaibhav Jadhav, Daniel Ivansson and Nicole Borth, A CRISPR/Cas9 based engineering strategy for overexpression of multiple genes in Chinese hamster ovary cells, *Metabolic Engineering*, https://doi.org/10.1016/j.ymben.2018.05.017

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

A CRISPR/Cas9 based engineering strategy for overexpression of multiple genes in Chinese hamster ovary cells

Peter Eisenhut^{a,b}, Gerald Klanert^{a,b}, Marcus Weinguny^{a,b}, Laurenz Baier^{a,b}, Vaibhav Jadhav^{a,b}, Daniel Ivansson^c, Nicole Borth^{a,b}

^aACIB Gmbh, Austrian Centre of Industrial Biotechnology, Vienna, Austria

^bDepartment of Biotechnology, University of Natural Resources and Life Sciences,

Vienna, Vienna, Austria

^cGE Healthcare Bio-Science AB, Uppsala, Sweden

*Correspondence: Dr. Nicole Borth, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, 1190 Vienna, Austria nicole.borth@boku.ac.at

Abstract

Manipulation of multiple genes to engineer Chinese Hamster Ovary (CHO) cells for better performance in production processes of biopharmaceuticals has recently become more and more popular. Yet, identification of useful genes and the unequivocally assessment of their effect alone and in combination(s) on the cellular phenotype is difficult due to high variation between subclones. Here, we present development and proof-of-concept of a novel engineering strategy using multiplexable activation of Download English Version:

https://daneshyari.com/en/article/6494038

Download Persian Version:

https://daneshyari.com/article/6494038

Daneshyari.com